A5037225502- Cutaneous lymphoproliferative disorders research
- Fungal Infections and Studies
- Chronic Lymphocytic Leukemia Research
- Vascular Tumors and Angiosarcomas
- T-cell and Retrovirus Studies
- Lymphoma Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Urologic and reproductive health conditions
- Autoimmune Bullous Skin Diseases
- Mast cells and histamine
- Urological Disorders and Treatments
- Systemic Sclerosis and Related Diseases
- Nail Diseases and Treatments
- Retinoids in leukemia and cellular processes
- Genital Health and Disease
San Gallicano Hospital
2022-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2008-2024
Istituti Fisioterapici Ospitalieri
2008
Background Topical chlormethine (CL) is recommended as a first-line treatment for early-stage mycosis fungoides (MF) and in 2017, the European Medicines Agency approved CL gel formulation to treat adult patients. More recently, increase patient compliance adherence, clinicians have developed flexible protocols that allow concomitant use of with topical corticosteroids daily practice regimens. Therefore, sharing real-life data on side effects management may help improve this agent. Objectives...
Treatment choices for patients with advanced-stage mycosis fungoides (MF) or Sézary syndrome (SS) who have failed first-line systemic therapies can be challenging, as several options are available. However, most evidence is based on observational and early phase studies due to the rarity of disease. Mogamulizumab has recently been approved treatment adult MF SS received at least one prior therapy; it a good tolerability profile prompting its use in combination other agents. This article aims...
Topical chlormethine (CL) gel formulation was approved by the EMA in 2017 for treatment of adult patients with mycosis fungoides (MF). To expand knowledge on management MF, this paper provides an overview clinical practice evidence about MF diagnostic phase and a collection experiences to better characterize use CL daily practice. Collected cases underline importance concomitant biopsy evaluation phase, contribution multidisciplinary team, support as first-line or adjuvant selected patients.